Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183

Benzinga · 3d ago
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $163 to $183.